中國交通建設(01800.HK)上半年淨利預增109.70%-139.01%
格隆匯7月23日丨中國交通建設(01800.HK)公佈,按照中國企業會計準則,公司預計2021年半年度實現歸屬於上市公司普通股股東的淨利潤(扣除歸屬於少數股東的淨利潤)為人民幣85.41億元到人民幣97.35億元,與上年同期相比將增加人民幣44.68億元到人民幣56.62億元,同比增長109.70%到139.01%。
公吿稱,一方面,去年上半年疫情期間,國內高速公路免收車輛過路費對公司的影響該年度已消除;另一方面,公司按照"兩保一爭"的戰略目標,牢固樹立"過緊日子"思想,加強對盈利改善、財務槓桿風險及兩金等關鍵指標的管理,經營業績和經營質量持續穩中向好。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.